ELDN logo

ELDN
Eledon Pharmaceuticals Inc

6,835
Mkt Cap
$235.14M
Volume
971,067.00
52W High
$4.60
52W Low
$1.35
PE Ratio
-5.22
ELDN Fundamentals
Price
$3.10
Prev Close
$3.10
Open
$3.10
50D MA
$2.59
Beta
0.96
Avg. Volume
1.53M
EPS (Annual)
-$0.5574
P/B
2.88
Rev/Employee
$0.00
$46.57
Loading...
Loading...
News
all
press releases
SG Americas Securities LLC Makes New Investment in Eledon Pharmaceuticals, Inc. $ELDN
SG Americas Securities LLC bought a new position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines PR Newswire VANCOUVER, BC, April 6, 2026 Issued on behalf...
PR Newswire·6d ago
News Placeholder
Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Rises By 30.3%
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) saw a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 8,417,915 shares, an...
MarketBeat·14d ago
News Placeholder
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Analysts
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) has received an average recommendation of "Hold" from the five brokerages that are presently covering the firm, Marketbeat.com reports...
MarketBeat·17d ago
News Placeholder
Eledon Pharmaceuticals (NASDAQ:ELDN) Announces Quarterly Earnings Results, Beats Expectations By $0.10 EPS
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.10...
MarketBeat·24d ago
News Placeholder
Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference
Eledon Pharmaceuticals (NASDAQ:ELDN) used a presentation at the Leerink Partners Global Healthcare Conference to highlight what CEO David-Alexandre Gros described as a rapid expansion in clinical...
MarketBeat·28d ago
News Placeholder
Eledon Pharmaceuticals (ELDN) to Release Quarterly Earnings on Thursday
Eledon Pharmaceuticals (NASDAQ:ELDN) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...
MarketBeat·1mo ago
News Placeholder
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance...
PR Newswire·1mo ago
News Placeholder
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Average Recommendation of "Hold" by Brokerages
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) has been given an average rating of "Hold" by the five research firms that are currently covering the stock, MarketBeat Ratings reports...
MarketBeat·1mo ago
News Placeholder
Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for Tego at Conference
Eledon Pharmaceuticals (NASDAQ:ELDN) executives discussed recent clinical results and upcoming regulatory plans for its investigational immunosuppressive therapy, referred to in the discussion as...
MarketBeat·2mo ago
<
1
2
...
>

Latest ELDN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.